BioSyent Announces Grant of Restricted Share Units
March 19 2021 - 4:33PM
BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX)
announces that its Board of Directors has approved a grant of
67,252 Restricted Share Units “RSUs” to certain directors,
officers, management, and employees of the Company pursuant to the
Company’s Restricted Share Unit Plan (the “RSU Plan”). These RSUs
will fully vest within three years on the third anniversary of the
applicable grant date.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community, specialty
and international business units.
As of the date of this press release, the
Company has 12,731,275 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
Biosyent (TSXV:RX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Jul 2023 to Jul 2024